Evidence map›Paper›PMID 42154065›Full record

Observational studyCancer immunology, immunotherapy : CII2026

Early increase of CD103 expression on peripheral PD-1

Satoko Sumimoto, Tomoki Makino, Shigeto Nakai, Takaomi Hagi, Kota Momose, Kotaro Yamashita, Takuro Saito, Koji Tanaka, Tsuyoshi Takahashi, Yukinori Kurokawa and 3 more

Abstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Cancer immunology, immunotherapy : CII, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Satoko SumimotoDepartment of Gastroenterological Surgery, The University of Osaka Graduate School of Medicine, 2-2-E2 Yamada-Oka, Suita, Osaka, 565-0871, Japan.
Tomoki MakinoDepartment of Gastroenterological Surgery, The University of Osaka Graduate School of Medicine, 2-2-E2 Yamada-Oka, Suita, Osaka, 565-0871, Japan. tmakino@gesurg.med.osaka-u.ac.jp.
Shigeto NakaiDepartment of Gastroenterological Surgery, The University of Osaka Graduate School of Medicine, 2-2-E2 Yamada-Oka, Suita, Osaka, 565-0871, Japan.
Takaomi HagiDepartment of Gastroenterological Surgery, The University of Osaka Graduate School of Medicine, 2-2-E2 Yamada-Oka, Suita, Osaka, 565-0871, Japan.
Kota MomoseDepartment of Gastroenterological Surgery, The University of Osaka Graduate School of Medicine, 2-2-E2 Yamada-Oka, Suita, Osaka, 565-0871, Japan.
Kotaro YamashitaDepartment of Gastroenterological Surgery, The University of Osaka Graduate School of Medicine, 2-2-E2 Yamada-Oka, Suita, Osaka, 565-0871, Japan.
Takuro SaitoDepartment of Gastroenterological Surgery, The University of Osaka Graduate School of Medicine, 2-2-E2 Yamada-Oka, Suita, Osaka, 565-0871, Japan.
Koji TanakaDepartment of Gastroenterological Surgery, The University of Osaka Graduate School of Medicine, 2-2-E2 Yamada-Oka, Suita, Osaka, 565-0871, Japan.
Tsuyoshi TakahashiDepartment of Gastroenterological Surgery, The University of Osaka Graduate School of Medicine, 2-2-E2 Yamada-Oka, Suita, Osaka, 565-0871, Japan.
Yukinori KurokawaDepartment of Gastroenterological Surgery, The University of Osaka Graduate School of Medicine, 2-2-E2 Yamada-Oka, Suita, Osaka, 565-0871, Japan.
Kiyokazu NakajimaDepartment of Gastroenterological Surgery, The University of Osaka Graduate School of Medicine, 2-2-E2 Yamada-Oka, Suita, Osaka, 565-0871, Japan.
Hidetoshi EguchiDepartment of Gastroenterological Surgery, The University of Osaka Graduate School of Medicine, 2-2-E2 Yamada-Oka, Suita, Osaka, 565-0871, Japan.
Yuichiro DokiDepartment of Gastroenterological Surgery, The University of Osaka Graduate School of Medicine, 2-2-E2 Yamada-Oka, Suita, Osaka, 565-0871, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundNivolumab has become a standard treatment for advanced or recurrent esophageal squamous cell carcinoma (ESCC). However, reliable blood-based biomarkers predictive of response remain undefined. We investigated dynamic changes in peripheral PD-1 PATIENTS AND

methodsFifty-seven patients with advanced or recurrent ESCC treated with nivolumab were enrolled in this retrospective observational study. Peripheral blood mononuclear cells were collected before treatment and at 1, 2, and 4 weeks after initiation. Flow cytometric analyses evaluated the expression of CD103, CD45RA, Tim-3, LAG-3, TIGIT, and Ki-67 among nivolumab-binding PD-1

resultsThe objective response rate was 24.6%, and the median overall survival (OS) was 11.7 months. CD103 expression among PD-1

conclusionsEarly elevation of CD103 expression among peripheral PD-1

Indexed as

Antineoplastic Agents, ImmunologicalCD8-Positive T-LymphocytesEsophageal NeoplasmsEsophageal Squamous Cell CarcinomaIntegrin alpha ChainsNivolumabProgrammed Cell Death 1 ReceptorAdultAgedAntigens, CDBiomarkers, TumorFemaleHumansMaleMiddle AgedRetrospective Studiesalpha E integrinsAntigens, CDAntineoplastic Agents, ImmunologicalBiomarkers, TumorIntegrin alpha ChainsNivolumabPDCD1 protein, humanProgrammed Cell Death 1 ReceptorCD103Esophageal cancerNivolumabT-cell

Identifiers

PMID42154065
PMCPMC13388847

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.